RNAi Drug Delivery Market

RNAi Drug Delivery Market Size (2023 to 2028)

The size of the global RNAi drug delivery market is estimated to be growing at a CAGR of 27.2% from 2023 to 2028. The size of the market is estimated to be worth USD 212.9 billion by 2028 from USD 63.75 billion in 2023.

RNAi is a defense mechanism employed by Eukaryotes to degrade exogenous genes such as viruses. It is exclusively called gene silencing. We can initiate this by injecting RNAi-based drugs into the human body called RNAi Drug Delivery. RNAi Drug Delivery is an emerging therapeutic method. This method is specific to the point and has fewer side effects. It is possible to cure cancer with this method by controlling gene mutation. From 2006 onwards, various clinical trials have been held, and people are investing billions in this market to approve and research different types of RNAi-based Drugs.

MARKET DRIVERS:

Factors such as the increasing prevalence of chronic diseases such as cancer and heart diseases and innovative drug delivery applications drive the global RNAi drug delivery market.

The rise in account of chronic diseases such as cancer and cardiac malfunctioning leads to a constant increase in demand for the RNAi drug delivery market across the world. Government authorities in developing countries are taking measures to provide advanced drug delivery options to all sections of people to enhance healthcare services, which is fuelling the growth of the Global RNAi drug delivery market. Also, medical research organizations are continually putting efforts into developing effective RNA therapeutics. An increasing number of academic research and activities are also catalyzing the growth of the global RNAi drug delivery market. Other factors boosting the development of the market are increased adoptions of innovative drug delivery technologies and enhancement of drugs by improving stability. Also, it reduces the risk of side effects and other complications in patients. Also, Research carried out in the RNA Therapeutic field has also amplified the growth in the Global RNA Drug Delivery Market.

Increased focus on research and development activities from private and public organizations on nanotechnology to meet the continually rising demand of the RNAi drug delivery method is expected to create more growth opportunities for the market over the forecast period. Increasing economies of the countries such as the UK, and Canada, and highly populated countries such as China and India, where healthcare is booming rapidly, is creating a wide range of opportunities for the stakeholders and others involved in the global RNAi drug delivery market.

MARKET RESTRAINTS:

High investment and strict regulations are some of the major restraints of this market. The delivery of RNAi Drugs to specific tissues is the key challenge faced by the market. High costs associated with research are restraining the market and are expected to challenge the growth of the global RNAi drug delivery market. Other factors that challenge the market's development are inappropriate regulations, high risk of failure, shortage of skilled professionals in drug control laboratories, and lack of proper distribution networks of RNAi drug delivery due to the inadequate infrastructure of healthcare in developing countries. Accurate delivery of RNA molecules is a critical challenge to the companies involved in the Global RNAi drug delivery market.

COVID-19 impact on the global RNAi drug delivery market:

The Corona Virus is a quickly emerging disease across the globe with destructive conclusions. The impact of COVID-19 is affecting significant markets worldwide. Due to the pandemic, the pharmaceutical industry supply chain operations are being prominently restricted. The RNAi drug delivery market key players concentrate on developing vaccines taking the help of gene silencing technology, which is anticipated to propel the RNAi drug delivery market growth. The natural RNAi process may be engaged in developing superior-quality therapies to overcome the virus. Moreover, this procedure enables specific binding and silencing of therapeutic targets using Short interfering RNA (siRNA). Moreover, as COVID-19 is expected to continue worldwide, fundamental growth is seen in the demand for RNAi drug delivery technologies, which impels the market growth during the assessment period.

REPORT COVERAGE:

This research report on the global RNAi drug delivery market has been segmented and sub-segmented based on drug delivery, therapeutic application, and region.

RNAi Drug Delivery Market - By Drug Delivery:

• Nanoparticle Drug Delivery Technology
• Nucleic Acid Drug Delivery Technology
• Aptamer Drug Delivery Technology
• Pulmonary Drug Delivery Technology

Based on drug delivery, Nanoparticle Drug Delivery is the largest sub-segment in this market because of its use in drugs' selected delivery. However, aptamer drug delivery technology is the fastest-growing segment.

RNAi Drug Delivery Market - By Therapeutic Application:

• Infectious Diseases
• Cardiology
• Oncology
• Neurology
• Ophthalmology
• Metabolic Disorders

Based on the therapeutic application, the oncology segment is projected to lead the market during the forecast period due to the increasing prominence of targeted RNAi therapies for treating cancer patients and increasing research collaborations.

Cardiology therapeutic application is expected to have rapid growth in the RNAi drug delivery market across the world during the forecast period.

RNAi Drug Delivery Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Geographically, North America accounted for the largest share of the global RNAi drug delivery market in 2022, followed by Europe because of its high investments. The market in United States was dominating the North American RNAi drug delivery market and followed by Canada in 2022.

Europe is expected to have promising growth in the global RNAi drug delivery market during the forecast period. The number of chronic cases is surging development during the assessment period. The UK is anticipated to have the largest share. 

However, the Asia-Pacific market is expected to increase at the highest CAGR in the following five years because of increasing investments by the major players in this region. Japan, China, and India are predicted to grow quickly in the historical period due to the huge investments made by most of the companies present in the region.

Latin America and the Middle East & African regions in the RNAi drug delivery market are likely to have a steady and constant growth rate over the period.

KEY MARKET PLAYERS:

Some of the noteworthy market participants dominating the global RNAi drug delivery market profiled in this report are Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Tekmira Pharmaceuticals Corp, Isis Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp, Quark Pharmaceuticals Inc, Silence Therapeutics plc, Traversa Therapeutics Inc, Tacere Therapeutics Inc, Sirnaomics Inc, PhaseRx Inc.

RECENT MARKET HAPPENINGS:

• Alnylam Pharmaceuticals Inc. developed an RNA-based drug called lumasiran, which can be applied to treat PH1. The company has submitted an application under NDA to the U.S Food and drug administration. The company received approval for lumasiran from the FDA in Jan 2020. Also, In November 2019, Alnylam Pharmaceuticals Inc. received approval from the FDA for their RNA therapeutic drug called GIVLAARI, which is effectively used for treatments such as hypertension, liver and kidney diseases, genetic diseases, negative impact on the quality of life in adults diagnosed with Acute Hepatic porphyria.
• In Jan 2020, Dicerna Pharmaceutical Inc. announced that the company has entered into a strategic partnership with Novo Nordisk to develop innovative therapies for cardiac diseases associated with the liver, with the help of GalXY RNAi platform technology, which is set by Dicerna.
• In August 2018, the FDA approved a new drug called Onpattro, which comes under a new classification of drugs called small interfering RNA treatment for polyneuropathy patients. This new drug's approval allows professionals to eliminate haTTR and control polyneuropathy conditions by targeting the root cause in depth.